<DOC>
	<DOC>NCT00335699</DOC>
	<brief_summary>The primary objective of this study is to compare the effect of rosuvastatin 10mg with atorvastatin 10mg in the percentage reduction of LDL-C in Subjects with metabolic syndrome after 6 weeks of treatment.</brief_summary>
	<brief_title>Korean Rosuvastatin Effectiveness Study in Nondiabetic Metabolic Syndrome</brief_title>
	<detailed_description />
	<mesh_term>Hypercholesterolemia</mesh_term>
	<mesh_term>Metabolic Syndrome X</mesh_term>
	<mesh_term>Rosuvastatin Calcium</mesh_term>
	<criteria>Metabolic syndrome patient; Presence of 3 or more of the following: Abdominal obesity (waist circumference): men &gt; 90cm(36 inch), women &gt; 80cm(32 inch) Triglycerides ≥ 150 mg/dL (1.70 mmol/L) HDLC: men &lt; 40 mg/dL (1.04 mmol/L), women &lt; 50 mg/dL (1.3 mmol/L) BP ≥130/≥85 mmHg or subject receiving antihypertensive treatment Fasting blood glucose 110 mg dL (6.11 mmol/L) 125 mg/dL (6.94 mmol.L) Elevated LDLC concentrations reported within 4 weeks of visit 1 as follows; ≥ 130 mg/dL (3.36 mmol/L) to &lt; 220 mg/dL (5.69 mmol/L) in statin naive subjects (subjects who have not taken any lipidlowering therapy known to affect LDLC in the 4 weeks prior to visit 1) ≥ 100 mg/dL (2.59 mmol/L) to &lt; 160 mg/dL (4.14 mmol/L) in subjects who have taken a lipid lowering drug(s) within 4 weeks of visit 1 Triglyceride levels &lt; 400 mg/dL (4.52 mmol/L) Women of childbearing potential should be using a medically acceptable form of chemical or mechanical contraception. History of known diabetes mellitus Use of antihyperglycaemic medication. History of serious or hypersensitivity reactions to HMGCoA reductase inhibitors, in particular history of myopathy. No CHD or CHD Risk Equivalents and 01 Risk factors and Framingham 10Year risk is &lt;10%. History of heterozygous or homozygous familial hypercholesterolaemia or known type III hyperlipoproteinaemia (familial dysbetalipoproteinaemia). Active arterial disease such as unstable angina pectoris, myocardial infarction, transient ischaemic attack (TIA), cerebrovascular accident (CVA), coronary artery bypass surgery (CABG) or angioplasty within 2 months prior to entry in the dietary lead in period Uncontrolled hypothyroidism defined as thyroid stimulating hormone (TSH) &gt; 1.5 times the upper limit of normal (ULN) at Visit 2 or subjects whose thyroid replacement therapy was initiated within 3 months of entry into dietary leadin phase. Current active liver disease (alanine aminotransferase [ALT] &gt; 2 x ULN) or severe hepatic impairment. Unexplained serum CK &gt;3 times ULN (e.g. not due to recent trauma, intramuscular injections, heavy exercise, etc). Serum creatinine &gt; 176 umol/L (2.0 mg/dL) History of alcohol, or drug, abuse or both.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2007</verification_date>
	<keyword>Hypercholesterolemia with nondiabetic metabolic syndrome</keyword>
</DOC>